Cephalosporin analogues
    31.
    发明授权
    Cephalosporin analogues 失效
    头孢菌素类似物

    公开(公告)号:US4197402A

    公开(公告)日:1980-04-08

    申请号:US15180

    申请日:1979-02-26

    IPC分类号: C07D505/00 C07D498/00

    CPC分类号: C07D505/00

    摘要: 1-Oxa-cephalosporin analogues of the formula: ##STR1## [wherein X is 3-thienylmalonyl, phenylmalonyl, 4-hydroxyphenylmalonyl, or 2-fluoro-4-hydroxyphenylmalonyl;Y is hydrogen or methoxy; andR is hydrogen, alkali metal, or alkaline earth metal]and the preparation thereof.

    摘要翻译: 具有下式的1-氧杂 - 头孢菌素类似物:其中X是3-噻吩基丙二酰基,苯基丙二酸,4-羟基苯基丙二酸或2-氟-4-羟基苯基丙二酰基; Y是氢或甲氧基; 和R是氢,碱金属或碱土金属]及其制备。

    Haloarylmalonamidooxacephalosporins
    32.
    发明授权
    Haloarylmalonamidooxacephalosporins 失效
    卤代芳基丙酰胺氧基头孢菌素

    公开(公告)号:US4183928A

    公开(公告)日:1980-01-15

    申请号:US900235

    申请日:1978-04-26

    CPC分类号: C07C59/56 C07D505/00

    摘要: Antibacterial haloarylmalonamido-1-dethia-1-oxacephalosporins of the following formula: ##STR1## wherein Ar is ##STR2## (in which Hal and Hal' each is halogen and RO is hydroxy or protected hydroxy);COA and COB each is carboxy or protected carboxy including a pharmaceutically acceptable salt group;and Het is 1-lower alkyl-5-tetrazolyl, 1,3,4-thiadiazol-2-yl or 5-lower alkyl-1,3,4-thiadiazol-2-yl,a pharmaceutical or veterinary composition comprising the said haloarylmalonamido-1-dethia-1-oxacephalosporin and pharmaceutical carrier, and a method for treating or preventing human or veterinary infectious diseases comprising administering an effective amount of the said antibacterial compound.

    摘要翻译: 其中Ar是卤素,Hal和Hal各自为卤素,RO为羟基或被保护的羟基)的抗菌卤代芳基丙二酰胺-1-脱氧-1-氧杂七环素:其中Ar为< ; COA和COB各自为羧基或受保护的羧基,包括药学上可接受的盐基; 和Het是1-低级烷基-5-四唑基,1,3,4-噻二唑-2-基或5-低级烷基-1,3,4-噻二唑-2-基,其包含所述卤代芳基丙二酰胺 -1-脱氢-1-氧杂环孢菌素和药物载体,以及治疗或预防人或兽传感疾病的方法,包括给予有效量的所述抗菌化合物。

    3-Unsubstituted-3-cephem compounds
    34.
    发明授权
    3-Unsubstituted-3-cephem compounds 失效
    3-取代-3-头孢烯化合物

    公开(公告)号:US4254119A

    公开(公告)日:1981-03-03

    申请号:US74811

    申请日:1979-09-11

    CPC分类号: C07D277/587 Y02P20/55

    摘要: Antibacterial compounds represented by the following formula including their pharmaceutically acceptable salts and esters; process for preparing them; pharmaceutical preparation comprising them; and method for combating infections by administering them: ##STR1## (wherein Hal is halogen;R.sup.1 is hydrogen or an amino-protecting group;R.sup.2 is alkyl; andR.sup.3 is hydrogen or a carboxy-protecting group.)

    摘要翻译: 由下式表示的抗菌化合物包括其药学上可接受的盐和酯; 准备工作的过程; 包含它们的药物制剂; 以及通过施用它们来对抗感染的方法:其中Hal是卤素; R1是氢或氨基保护基; R2是烷基; R3是氢或羧基保护基。

    Vinylthioacetamido oxacephalosporin derivatives
    35.
    发明授权
    Vinylthioacetamido oxacephalosporin derivatives 失效
    乙烯基硫代乙酰氨基氧杂环孢菌素衍生物

    公开(公告)号:US4529721A

    公开(公告)日:1985-07-16

    申请号:US534147

    申请日:1983-09-21

    摘要: A compound of the formula: ##STR1## wherein u represents hydrogen, carboxamido, N-hydroxycarboxamido, carboxy, azido, an aryl, an acylamino, a protected carboxy or an N-alkoxycarboxamido, or, together with v, can represent --S-- or --CH.sub.2 S--; v represents hydrogen, halogen, cyano or an alkylthio, or, together with u, can represent --S-- or --CH.sub.2 S--, or, together with w, can represent --(CH.sub.2).sub.3 CO--; w represents hydrogen, carboamoyl, cyano, carboxy, an N-alkylcarbamoyl, an alkyl, an aryl, a protected carboxy or a heterocycle, or, together with v, can represents --(CH.sub.2).sub.3 CO--; x represents halogen, trifluoromethyl, an alkylthio or an arylthio; y represents hydrogen, a light metal or a carboxylic acid protecting group; and z represents an acyloxy or a heterocycle-thio, each of the above radicals represented by the symbols u, v, w, x, y and z being optionally substituted by halogen or a carbon-, nitrogen-, oxygen- or sulfur-containing functional group, a process for preparing the compound, a pharmaceutical composition containing the compound, and a therapeutical use of the compound.A compound of the formula: ##STR2## wherein u, v, w and x are as defined above, useful as a starting compound for preparing the compound (I) is also provided.

    摘要翻译: 下式的化合物:其中u表示氢,甲酰氨基,N-羟基羧甲酰氨基,羧基,叠氮基,芳基,酰氨基,被保护的羧基或N-烷氧基羧酰胺基,或与v一起可代表 -S-或-CH2S-; v表示氢,卤素,氰基或烷硫基,或与u一起可以表示-S-或-CH 2 S-,或者与w一起可以表示 - (CH 2)3 CO-; w表示氢,氨甲酰基,氰基,羧基,N-烷基氨基甲酰基,烷基,芳基,保护的羧基或杂环,或与v一起可以表示 - (CH 2)3 CO-; x表示卤素,三氟甲基,烷硫基或芳硫基; y表示氢,轻金属或羧酸保护基; 和z表示酰氧基或杂环硫基,由符号u,v,w,x,y和z表示的上述基团中的每一个任选被卤素或含碳,氮,氧或硫的 官能团,制备该化合物的方法,含该化合物的药物组合物和该化合物的治疗用途。 还提供了下式化合物:其中u,v,w和x如上定义,可用作制备化合物(I)的起始化合物。

    5-Fluorouracil derivatives
    38.
    发明授权
    5-Fluorouracil derivatives 失效
    5-氟尿嘧啶衍生物

    公开(公告)号:US4394505A

    公开(公告)日:1983-07-19

    申请号:US369110

    申请日:1982-04-16

    摘要: Novel 5-fluorouracil derivatives of the following general formula ##STR1## wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.5 alkyl, C.sub.6 -C.sub.10 aryl, C.sub.7 -C.sub.10 aralkyl, C.sub.1 -C.sub.12 alkanoyl, C.sub.2 -C.sub.6 alkoxycarbonyl, C.sub.1 -C.sub.5 alkanoyloxymethyl, carbamoyl or tri-C.sub.1 -C.sub.5 alkylsilyl;R.sup.2 is hydrogen, C.sub.1 -C.sub.5 alkyl, C.sub.6 -C.sub.10 aryl or C.sub.7 -C.sub.10 aralkyl;X is hydrogen, halogen or C.sub.2 -C.sub.6 alkoxycarbonyl;Y is O, NR' (R' is hydrogen or C.sub.1 -C.sub.5 alkyl), S, SO or SO.sub.2 ; andn is an integer of 1-3.which are orally administrable anti-tumor agents.

    摘要翻译: 新的5-氟尿嘧啶衍生物,其通式如下:其中R1是氢,C1-C5烷基,C6-C10芳基,C7-C10芳烷基,C1-C12烷酰基,C2-C6烷氧基羰基,C1-C5烷酰氧基甲基,氨基甲酰基或三C1-C5烷基甲硅烷基 ; R2是氢,C1-C5烷基,C6-C10芳基或C7-C10芳烷基; X是氢,卤素或C 2 -C 6烷氧基羰基; Y是O,NR'(R'是氢或C 1 -C 5烷基),S,SO或SO 2; n为1-3的整数。 其是口服给药的抗肿瘤剂。

    Arylmalonamido-1-oxadethiacephalosporins
    39.
    发明授权
    Arylmalonamido-1-oxadethiacephalosporins 失效
    芳基丙二酰胺-1-氧杂硫菌醚

    公开(公告)号:US4138486A

    公开(公告)日:1979-02-06

    申请号:US780183

    申请日:1977-03-22

    摘要: Antibacterial 1-oxadethiacephalosporins of the formula: ##STR1## [wherein Ar is ##STR2## (in which Acyl is organic or inorganic acyl); COB.sup.1 and COB.sup.2 each is carboxy or protected carboxy; Het is ##STR3## (in which COB.sup.3 is carboxy or protected carboxy); AND Y is hydrogen or methoxy;And when COB.sup.1, COB.sub.2, and/or COB.sup.3 is carboxy, pharmaceutically acceptable salts thereof are included,But with a proviso that when Y is methoxy, Het is ##STR4## a pharmaceutical or veterinary composition comprising the said 1-oxadethiacephalosporins and pharmaceutical carrier, and a method for treating or preventing human or veterinary infectious diseases comprising administering the said 1-oxadethiacephalosporin.

    摘要翻译: 下式的抗菌1-恶二硫醚孢子:其中Ar是有机或无机酰基;其中Ar是有机或无机酰基; COB1和COB2各自为羧基或保护的羧基; Het是(其中COB 3是羧基或被保护的羧基); 且Y为氢或甲氧基; 当COB1,COB2和/或COB3为羧基时,包括其药学上可接受的盐,但是当Y为甲氧基时,Het为包含所述1-恶二硫醚类和药物载体的药物或兽用组合物, 以及用于治疗或预防人或兽传染性疾病的方法,包括施用所述1-恶二硫醚类。

    Sample information measuring method and scanning confocal microscope
    40.
    发明授权
    Sample information measuring method and scanning confocal microscope 有权
    样品信息测量方法和扫描共聚焦显微镜

    公开(公告)号:US07205531B2

    公开(公告)日:2007-04-17

    申请号:US10991123

    申请日:2004-11-17

    IPC分类号: H01J3/14 G02B21/00

    CPC分类号: G02B21/006

    摘要: When irradiating a sample with light from a light source through an object lens, discretely changing a relative position between a beam condensing position of the object lens and the sample in an optical axis direction of the converging beam, obtaining light intensity information from the sample at each relative position, extracting plural pieces of light intensity information from a light intensity information group, estimating a maximum value on a change curve adaptive to the plural pieces of extracted light intensity information and the relative position for the maximum value, and obtaining the estimated maximum value of the light intensity information and relative position as brightness information and height information, these information about the sample can be continuously obtained by discretely performing an iterative operation on the relative position between a beam condensing position of the object lens and the sample in an optical axis direction of the converging beam.

    摘要翻译: 当通过物镜将来自光源的光照射样品时,离散地改变物镜的聚光位置和聚光束的光轴方向上的样品之间的相对位置,从样品中获得光强度信息 每个相对位置,从光强度信息组中提取多个光强度信息,根据多个提取的光强度信息和最大值的相对位置估计适应于变化曲线的最大值,并获得估计的最大值 光强度信息的值和相对位置作为亮度信息和高度信息,关于样本的这些信息可以通过离散地对物镜的光束聚光位置和光学器件的样品之间的相对位置进行迭代操作来连续获得 会聚光束的轴向。